MXPA03009563A - Incorporacion in vivo de aminoacidos no naturales. - Google Patents
Incorporacion in vivo de aminoacidos no naturales.Info
- Publication number
- MXPA03009563A MXPA03009563A MXPA03009563A MXPA03009563A MXPA03009563A MX PA03009563 A MXPA03009563 A MX PA03009563A MX PA03009563 A MXPA03009563 A MX PA03009563A MX PA03009563 A MXPA03009563 A MX PA03009563A MX PA03009563 A MXPA03009563 A MX PA03009563A
- Authority
- MX
- Mexico
- Prior art keywords
- amino acid
- protein
- cell
- receptor
- factor
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 523
- 238000001727 in vivo Methods 0.000 title claims abstract description 30
- 238000010348 incorporation Methods 0.000 title abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 359
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 315
- 238000000034 method Methods 0.000 claims abstract description 183
- 239000000203 mixture Substances 0.000 claims abstract description 101
- 229940024606 amino acid Drugs 0.000 claims description 543
- 235000001014 amino acid Nutrition 0.000 claims description 543
- 235000018102 proteins Nutrition 0.000 claims description 309
- 210000004027 cell Anatomy 0.000 claims description 222
- 108020004705 Codon Proteins 0.000 claims description 133
- 238000013519 translation Methods 0.000 claims description 103
- -1 tyrosine amino acid Chemical class 0.000 claims description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 241000588724 Escherichia coli Species 0.000 claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 108020005038 Terminator Codon Proteins 0.000 claims description 42
- 229920001184 polypeptide Polymers 0.000 claims description 38
- 230000015572 biosynthetic process Effects 0.000 claims description 35
- 239000013612 plasmid Substances 0.000 claims description 34
- 150000007523 nucleic acids Chemical class 0.000 claims description 33
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 33
- 102000003951 Erythropoietin Human genes 0.000 claims description 32
- 108090000394 Erythropoietin Proteins 0.000 claims description 32
- 229940105423 erythropoietin Drugs 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 31
- 229960004441 tyrosine Drugs 0.000 claims description 31
- 230000001225 therapeutic effect Effects 0.000 claims description 30
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 29
- 230000001851 biosynthetic effect Effects 0.000 claims description 29
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 claims description 28
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 claims description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 28
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 26
- 238000000338 in vitro Methods 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 24
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 24
- 102100020880 Kit ligand Human genes 0.000 claims description 24
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 23
- 101710177504 Kit ligand Proteins 0.000 claims description 22
- 210000000440 neutrophil Anatomy 0.000 claims description 22
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 claims description 21
- 230000000295 complement effect Effects 0.000 claims description 21
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 claims description 21
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 19
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 19
- 102000013275 Somatomedins Human genes 0.000 claims description 18
- 239000003102 growth factor Substances 0.000 claims description 18
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 17
- 230000002757 inflammatory effect Effects 0.000 claims description 17
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 17
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 16
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 16
- 231100000331 toxic Toxicity 0.000 claims description 16
- 230000002588 toxic effect Effects 0.000 claims description 16
- 239000003053 toxin Substances 0.000 claims description 16
- 231100000765 toxin Toxicity 0.000 claims description 16
- 108700012359 toxins Proteins 0.000 claims description 16
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 15
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 15
- 101150013553 CD40 gene Proteins 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 14
- 102000004877 Insulin Human genes 0.000 claims description 14
- 108090001061 Insulin Proteins 0.000 claims description 14
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 14
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 14
- 230000001413 cellular effect Effects 0.000 claims description 14
- 229940125396 insulin Drugs 0.000 claims description 14
- 210000001616 monocyte Anatomy 0.000 claims description 14
- 229960005190 phenylalanine Drugs 0.000 claims description 14
- 150000002993 phenylalanine derivatives Chemical class 0.000 claims description 14
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 14
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 13
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 13
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 13
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 13
- 102000000589 Interleukin-1 Human genes 0.000 claims description 13
- 108010002352 Interleukin-1 Proteins 0.000 claims description 13
- 108090000340 Transaminases Proteins 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 12
- 108010002350 Interleukin-2 Proteins 0.000 claims description 12
- 102000000588 Interleukin-2 Human genes 0.000 claims description 12
- 108090001007 Interleukin-8 Proteins 0.000 claims description 12
- 102000004890 Interleukin-8 Human genes 0.000 claims description 12
- 102000015696 Interleukins Human genes 0.000 claims description 12
- 108010063738 Interleukins Proteins 0.000 claims description 12
- 108020004485 Nonsense Codon Proteins 0.000 claims description 12
- 108700020796 Oncogene Proteins 0.000 claims description 12
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 12
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 12
- 238000009739 binding Methods 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 235000000346 sugar Nutrition 0.000 claims description 12
- 102000014898 transaminase activity proteins Human genes 0.000 claims description 12
- BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 claims description 11
- 102400001368 Epidermal growth factor Human genes 0.000 claims description 11
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 11
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 11
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 11
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 11
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 11
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 11
- 102000014150 Interferons Human genes 0.000 claims description 11
- 108010050904 Interferons Proteins 0.000 claims description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 11
- 108010001831 LDL receptors Proteins 0.000 claims description 11
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 11
- 102000043276 Oncogene Human genes 0.000 claims description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 11
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 11
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 11
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 11
- 230000008901 benefit Effects 0.000 claims description 11
- 229940116977 epidermal growth factor Drugs 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 229940125863 peptide 78 Drugs 0.000 claims description 11
- 108010012038 peptide 78 Proteins 0.000 claims description 11
- 239000000813 peptide hormone Substances 0.000 claims description 11
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 11
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 10
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 10
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 10
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 10
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 10
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 10
- 102000004140 Oncostatin M Human genes 0.000 claims description 10
- 108090000630 Oncostatin M Proteins 0.000 claims description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- 108010022394 Threonine synthase Proteins 0.000 claims description 10
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 10
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 10
- 102000001307 androgen receptors Human genes 0.000 claims description 10
- 108010080146 androgen receptors Proteins 0.000 claims description 10
- 230000001746 atrial effect Effects 0.000 claims description 10
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 10
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 10
- 239000002934 diuretic Substances 0.000 claims description 10
- 102000015694 estrogen receptors Human genes 0.000 claims description 10
- 108010038795 estrogen receptors Proteins 0.000 claims description 10
- 229940079322 interferon Drugs 0.000 claims description 10
- 230000001452 natriuretic effect Effects 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 10
- 102000003998 progesterone receptors Human genes 0.000 claims description 10
- 108090000468 progesterone receptors Proteins 0.000 claims description 10
- 230000019491 signal transduction Effects 0.000 claims description 10
- 108010029697 CD40 Ligand Proteins 0.000 claims description 9
- 102100032937 CD40 ligand Human genes 0.000 claims description 9
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 9
- 241000238631 Hexapoda Species 0.000 claims description 9
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 9
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 9
- 239000000854 Human Growth Hormone Substances 0.000 claims description 9
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 9
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 9
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
- 102000006834 complement receptors Human genes 0.000 claims description 9
- 108010047295 complement receptors Proteins 0.000 claims description 9
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 9
- 108091006106 transcriptional activators Proteins 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- WTFXTQVDAKGDEY-UHFFFAOYSA-N (-)-chorismic acid Natural products OC1C=CC(C(O)=O)=CC1OC(=C)C(O)=O WTFXTQVDAKGDEY-UHFFFAOYSA-N 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 8
- 206010054094 Tumour necrosis Diseases 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- 102000005969 steroid hormone receptors Human genes 0.000 claims description 8
- 108020003113 steroid hormone receptors Proteins 0.000 claims description 8
- HWDZIRSKXFAMFU-UHFFFAOYSA-N 3-(4-aminophenyl)pyruvic acid Chemical compound NC1=CC=C(CC(=O)C(O)=O)C=C1 HWDZIRSKXFAMFU-UHFFFAOYSA-N 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 101710088194 Dehydrogenase Proteins 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 7
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims description 7
- 102100026720 Interferon beta Human genes 0.000 claims description 7
- 108090000467 Interferon-beta Proteins 0.000 claims description 7
- 229930194542 Keto Natural products 0.000 claims description 7
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 7
- 241001442654 Percnon planissimum Species 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 230000001976 improved effect Effects 0.000 claims description 7
- 125000000468 ketone group Chemical group 0.000 claims description 7
- 101150070717 papA gene Proteins 0.000 claims description 7
- 101150014077 papB gene Proteins 0.000 claims description 7
- 101150061305 papC gene Proteins 0.000 claims description 7
- 102400000068 Angiostatin Human genes 0.000 claims description 6
- 108010079709 Angiostatins Proteins 0.000 claims description 6
- 102000007592 Apolipoproteins Human genes 0.000 claims description 6
- 108010071619 Apolipoproteins Proteins 0.000 claims description 6
- 108010083590 Apoproteins Proteins 0.000 claims description 6
- 102000006410 Apoproteins Human genes 0.000 claims description 6
- 101000716807 Arabidopsis thaliana Protein SCO1 homolog 1, mitochondrial Proteins 0.000 claims description 6
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 6
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 6
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 6
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 claims description 6
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 claims description 6
- 102100032912 CD44 antigen Human genes 0.000 claims description 6
- 102000055006 Calcitonin Human genes 0.000 claims description 6
- 108060001064 Calcitonin Proteins 0.000 claims description 6
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 6
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 101710104662 Enterotoxin type C-3 Proteins 0.000 claims description 6
- 101100057358 Escherichia coli (strain K12) atpA gene Proteins 0.000 claims description 6
- 101100271586 Escherichia coli (strain K12) atpD gene Proteins 0.000 claims description 6
- 101100218161 Escherichia coli (strain K12) atpG gene Proteins 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 102100030844 Exocyst complex component 1 Human genes 0.000 claims description 6
- 101150070197 F7-2 gene Proteins 0.000 claims description 6
- 108010076282 Factor IX Proteins 0.000 claims description 6
- 108010023321 Factor VII Proteins 0.000 claims description 6
- 108010054218 Factor VIII Proteins 0.000 claims description 6
- 102000001690 Factor VIII Human genes 0.000 claims description 6
- 108010049003 Fibrinogen Proteins 0.000 claims description 6
- 102000008946 Fibrinogen Human genes 0.000 claims description 6
- 102100037362 Fibronectin Human genes 0.000 claims description 6
- 108010067306 Fibronectins Proteins 0.000 claims description 6
- 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 claims description 6
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 claims description 6
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 6
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 108010051696 Growth Hormone Proteins 0.000 claims description 6
- 108090000031 Hedgehog Proteins Proteins 0.000 claims description 6
- 102000003693 Hedgehog Proteins Human genes 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 108010054147 Hemoglobins Proteins 0.000 claims description 6
- 102000007625 Hirudins Human genes 0.000 claims description 6
- 108010007267 Hirudins Proteins 0.000 claims description 6
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 6
- 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 claims description 6
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 claims description 6
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims description 6
- 101001076715 Homo sapiens RNA-binding protein 39 Proteins 0.000 claims description 6
- 101000652229 Homo sapiens Suppressor of cytokine signaling 7 Proteins 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 6
- 108010002616 Interleukin-5 Proteins 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 108010002335 Interleukin-9 Proteins 0.000 claims description 6
- 108010063045 Lactoferrin Proteins 0.000 claims description 6
- 108060001084 Luciferase Proteins 0.000 claims description 6
- 239000005089 Luciferase Substances 0.000 claims description 6
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 6
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 6
- 101100084009 Pediococcus acidilactici pedA gene Proteins 0.000 claims description 6
- 101100082835 Pediococcus acidilactici pedB gene Proteins 0.000 claims description 6
- 101100082836 Pediococcus acidilactici pedC gene Proteins 0.000 claims description 6
- 102100036154 Platelet basic protein Human genes 0.000 claims description 6
- 101100226151 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) estA gene Proteins 0.000 claims description 6
- 102000003743 Relaxin Human genes 0.000 claims description 6
- 108090000103 Relaxin Proteins 0.000 claims description 6
- 102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 108010056088 Somatostatin Proteins 0.000 claims description 6
- 102000005157 Somatostatin Human genes 0.000 claims description 6
- 101000882406 Staphylococcus aureus Enterotoxin type C-1 Proteins 0.000 claims description 6
- 101000882403 Staphylococcus aureus Enterotoxin type C-2 Proteins 0.000 claims description 6
- 101100185373 Streptococcus pneumoniae psaA gene Proteins 0.000 claims description 6
- 108010023197 Streptokinase Proteins 0.000 claims description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 6
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 6
- 102100030529 Suppressor of cytokine signaling 7 Human genes 0.000 claims description 6
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 6
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 6
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 6
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 6
- 108010082685 antiarrhythmic peptide Proteins 0.000 claims description 6
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 6
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 6
- 229960004015 calcitonin Drugs 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 231100000655 enterotoxin Toxicity 0.000 claims description 6
- 239000002095 exotoxin Substances 0.000 claims description 6
- 231100000776 exotoxin Toxicity 0.000 claims description 6
- 229960004222 factor ix Drugs 0.000 claims description 6
- 229940012413 factor vii Drugs 0.000 claims description 6
- 229960000301 factor viii Drugs 0.000 claims description 6
- 229940012952 fibrinogen Drugs 0.000 claims description 6
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 6
- 229940006607 hirudin Drugs 0.000 claims description 6
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 6
- 229940078795 lactoferrin Drugs 0.000 claims description 6
- 235000021242 lactoferrin Nutrition 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 230000002188 osteogenic effect Effects 0.000 claims description 6
- 239000000199 parathyroid hormone Substances 0.000 claims description 6
- 229960001319 parathyroid hormone Drugs 0.000 claims description 6
- 229920000570 polyether Polymers 0.000 claims description 6
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 6
- 229960000553 somatostatin Drugs 0.000 claims description 6
- 229960005202 streptokinase Drugs 0.000 claims description 6
- 231100000617 superantigen Toxicity 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 229960005356 urokinase Drugs 0.000 claims description 6
- YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 claims description 5
- 102000001902 CC Chemokines Human genes 0.000 claims description 5
- 108010040471 CC Chemokines Proteins 0.000 claims description 5
- 108050006947 CXC Chemokine Proteins 0.000 claims description 5
- 102000019388 CXC chemokine Human genes 0.000 claims description 5
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 5
- 108010086677 Gonadotropins Proteins 0.000 claims description 5
- 102000006771 Gonadotropins Human genes 0.000 claims description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 102000003815 Interleukin-11 Human genes 0.000 claims description 5
- 108090000177 Interleukin-11 Proteins 0.000 claims description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
- 108010015406 Neurturin Proteins 0.000 claims description 5
- 102000001839 Neurturin Human genes 0.000 claims description 5
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 5
- 108010035004 Prephenate Dehydrogenase Proteins 0.000 claims description 5
- 101710146427 Probable tyrosine-tRNA ligase, cytoplasmic Proteins 0.000 claims description 5
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 5
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 5
- 108010078233 Thymalfasin Proteins 0.000 claims description 5
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims description 5
- 101710107268 Tyrosine-tRNA ligase, mitochondrial Proteins 0.000 claims description 5
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000002587 anti-hemolytic effect Effects 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 5
- 238000004299 exfoliation Methods 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 5
- 239000002622 gonadotropin Substances 0.000 claims description 5
- 102000002467 interleukin receptors Human genes 0.000 claims description 5
- 108010093036 interleukin receptors Proteins 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 claims description 5
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 5
- 229960004231 thymalfasin Drugs 0.000 claims description 5
- YYTDJPUFAVPHQA-VKHMYHEASA-N (2s)-2-amino-3-(2,3,4,5,6-pentafluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(F)C(F)=C(F)C(F)=C1F YYTDJPUFAVPHQA-VKHMYHEASA-N 0.000 claims description 4
- PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 claims description 4
- XTXGLOBWOMUGQB-VIFPVBQESA-N (2s)-2-azaniumyl-3-(3-methoxyphenyl)propanoate Chemical compound COC1=CC=CC(C[C@H](N)C(O)=O)=C1 XTXGLOBWOMUGQB-VIFPVBQESA-N 0.000 claims description 4
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 claims description 4
- IBCKYXVMEMSMQM-JTQLQIEISA-N (2s)-3-(3-acetylphenyl)-2-aminopropanoic acid Chemical compound CC(=O)C1=CC=CC(C[C@H](N)C(O)=O)=C1 IBCKYXVMEMSMQM-JTQLQIEISA-N 0.000 claims description 4
- PZNQZSRPDOEBMS-QMMMGPOBSA-N 4-iodo-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(I)C=C1 PZNQZSRPDOEBMS-QMMMGPOBSA-N 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 108090000783 Renin Proteins 0.000 claims description 4
- 102100028255 Renin Human genes 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 4
- 101710120037 Toxin CcdB Proteins 0.000 claims description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 4
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 150000001299 aldehydes Chemical class 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 150000001615 biotins Chemical class 0.000 claims description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 229950006137 dexfosfoserine Drugs 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000002466 imines Chemical class 0.000 claims description 4
- TVIDEEHSOPHZBR-AWEZNQCLSA-N para-(benzoyl)-phenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C(=O)C1=CC=CC=C1 TVIDEEHSOPHZBR-AWEZNQCLSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 150000003573 thiols Chemical class 0.000 claims description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 4
- JZRBSTONIYRNRI-VIFPVBQESA-N 3-methylphenylalanine Chemical compound CC1=CC=CC(C[C@H](N)C(O)=O)=C1 JZRBSTONIYRNRI-VIFPVBQESA-N 0.000 claims description 3
- IRZQDMYEJPNDEN-UHFFFAOYSA-N 3-phenyl-2-aminobutanoic acid Natural products OC(=O)C(N)C(C)C1=CC=CC=C1 IRZQDMYEJPNDEN-UHFFFAOYSA-N 0.000 claims description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 3
- 108010055124 Chemokine CCL7 Proteins 0.000 claims description 3
- 229940124073 Complement inhibitor Drugs 0.000 claims description 3
- 239000004971 Cross linker Substances 0.000 claims description 3
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 claims description 3
- 108091032917 Transfer-messenger RNA Proteins 0.000 claims description 3
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 150000001576 beta-amino acids Chemical class 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000004074 complement inhibitor Substances 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 claims description 3
- 108091008039 hormone receptors Proteins 0.000 claims description 3
- FSPSELPMWGWDRY-UHFFFAOYSA-N m-Methylacetophenone Chemical compound CC(=O)C1=CC=CC(C)=C1 FSPSELPMWGWDRY-UHFFFAOYSA-N 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 230000001698 pyrogenic effect Effects 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 2
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 101710194492 SET-binding protein Proteins 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 101001057112 Staphylococcus aureus Enterotoxin type D Proteins 0.000 claims description 2
- 241001518258 Streptomyces pristinaespiralis Species 0.000 claims description 2
- 241000531819 Streptomyces venezuelae Species 0.000 claims description 2
- 102000016540 Tyrosine aminotransferases Human genes 0.000 claims description 2
- 108010042606 Tyrosine transaminase Proteins 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- PSWJVKKJYCAPTI-UHFFFAOYSA-N oxido-oxo-phosphonophosphanylphosphanium Chemical compound OP(O)(=O)PP(=O)=O PSWJVKKJYCAPTI-UHFFFAOYSA-N 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 101150028338 tyrB gene Proteins 0.000 claims description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 5
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims 4
- 108010055204 Chemokine CCL8 Proteins 0.000 claims 4
- 102000018997 Growth Hormone Human genes 0.000 claims 4
- 102000010445 Lactoferrin Human genes 0.000 claims 4
- 102100025336 Tyrosine-tRNA ligase, mitochondrial Human genes 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 4
- WTFXTQVDAKGDEY-HTQZYQBOSA-N chorismic acid Chemical compound O[C@@H]1C=CC(C(O)=O)=C[C@H]1OC(=C)C(O)=O WTFXTQVDAKGDEY-HTQZYQBOSA-N 0.000 claims 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims 4
- 210000002510 keratinocyte Anatomy 0.000 claims 3
- 108091006027 G proteins Proteins 0.000 claims 2
- 102000030782 GTP binding Human genes 0.000 claims 2
- 108091000058 GTP-Binding Proteins 0.000 claims 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 claims 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 claims 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- VBHQPSVGLVGLLD-JTQLQIEISA-N (2s)-2-amino-3-(3-ethylphenyl)propanoic acid Chemical compound CCC1=CC=CC(C[C@H](N)C(O)=O)=C1 VBHQPSVGLVGLLD-JTQLQIEISA-N 0.000 claims 1
- TZVOWUZAOVUUBP-UHFFFAOYSA-N 1-[3-(bromomethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(CBr)=C1 TZVOWUZAOVUUBP-UHFFFAOYSA-N 0.000 claims 1
- 101100366707 Arabidopsis thaliana SSL11 gene Proteins 0.000 claims 1
- 101001039702 Escherichia coli (strain K12) Methyl-accepting chemotaxis protein I Proteins 0.000 claims 1
- 102100022374 Homeobox protein DLX-4 Human genes 0.000 claims 1
- 101000901614 Homo sapiens Homeobox protein DLX-4 Proteins 0.000 claims 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101100366562 Panax ginseng SS12 gene Proteins 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 101150109894 TGFA gene Proteins 0.000 claims 1
- 239000003929 acidic solution Substances 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000001064 degrader Substances 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 210000002074 inflammatory monocyte Anatomy 0.000 claims 1
- 230000002608 insulinlike Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- VQHUWZGVPUQSFH-UHFFFAOYSA-N phosphonophosphanylphosphonic acid Chemical compound P(=O)(O)(O)PP(=O)(O)O VQHUWZGVPUQSFH-UHFFFAOYSA-N 0.000 claims 1
- 229940012957 plasmin Drugs 0.000 claims 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 108020004566 Transfer RNA Proteins 0.000 description 98
- 230000014616 translation Effects 0.000 description 72
- 108090000364 Ligases Proteins 0.000 description 59
- 102000003960 Ligases Human genes 0.000 description 58
- 102000004190 Enzymes Human genes 0.000 description 33
- 108090000790 Enzymes Proteins 0.000 description 33
- 229940088598 enzyme Drugs 0.000 description 33
- 239000003550 marker Substances 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 28
- 108091060545 Nonsense suppressor Proteins 0.000 description 17
- 230000002068 genetic effect Effects 0.000 description 17
- 230000000875 corresponding effect Effects 0.000 description 14
- 238000002703 mutagenesis Methods 0.000 description 14
- 231100000350 mutagenesis Toxicity 0.000 description 14
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 14
- 230000035772 mutation Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 235000002374 tyrosine Nutrition 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 235000008729 phenylalanine Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108010016529 Bacillus amyloliquefaciens ribonuclease Proteins 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 10
- 108010016626 Dipeptides Proteins 0.000 description 10
- 108010021466 Mutant Proteins Proteins 0.000 description 10
- 102000008300 Mutant Proteins Human genes 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000002741 site-directed mutagenesis Methods 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 108020005098 Anticodon Proteins 0.000 description 8
- 241000203407 Methanocaldococcus jannaschii Species 0.000 description 8
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 description 8
- 238000002823 phage display Methods 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 241000205062 Halobacterium Species 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 6
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000007429 general method Methods 0.000 description 6
- 235000004554 glutamine Nutrition 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 101150055766 cat gene Proteins 0.000 description 5
- 239000002975 chemoattractant Substances 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical class OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 235000008206 alpha-amino acids Nutrition 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- WTFXTQVDAKGDEY-HTQZYQBOSA-L chorismate(2-) Chemical compound O[C@@H]1C=CC(C([O-])=O)=C[C@H]1OC(=C)C([O-])=O WTFXTQVDAKGDEY-HTQZYQBOSA-L 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000011176 pooling Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108010074429 thiolsubtilisins Proteins 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- 238000006257 total synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000567139 Aeropyrum pernix Species 0.000 description 3
- 241000205042 Archaeoglobus fulgidus Species 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- ZKZBPNGNEQAJSX-REOHCLBHSA-N L-selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 description 3
- 108700005090 Lethal Genes Proteins 0.000 description 3
- 241001302042 Methanothermobacter thermautotrophicus Species 0.000 description 3
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 3
- 241000205156 Pyrococcus furiosus Species 0.000 description 3
- 241000522615 Pyrococcus horikoshii Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 101710137500 T7 RNA polymerase Proteins 0.000 description 3
- 241000039733 Thermoproteus thermophilus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 235000019647 acidic taste Nutrition 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 150000001371 alpha-amino acids Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000006229 amino acid addition Effects 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 150000002994 phenylalanines Chemical class 0.000 description 3
- 102000005162 pleiotrophin Human genes 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 235000016491 selenocysteine Nutrition 0.000 description 3
- 229940055619 selenocysteine Drugs 0.000 description 3
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 235000014393 valine Nutrition 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical class CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 2
- NIGWMJHCCYYCSF-QMMMGPOBSA-N 4-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-QMMMGPOBSA-N 0.000 description 2
- SJVJMFXCINSXFF-UHFFFAOYSA-N 5-(5-prop-1-ynylthiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C#CC)=CC=C1C1=CC=C(C(O)=O)S1 SJVJMFXCINSXFF-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 2
- 108020004256 Beta-lactamase Proteins 0.000 description 2
- 108090000746 Chymosin Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 2
- 102100024977 Glutamine-tRNA ligase Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010010369 HIV Protease Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 102100032241 Lactotransferrin Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940093740 amino acid and derivative Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 229940033495 antimalarials Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- 229940080701 chymosin Drugs 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006324 decarbonylation Effects 0.000 description 2
- 238000006606 decarbonylation reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 229940012426 factor x Drugs 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 108010051239 glutaminyl-tRNA synthetase Proteins 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 108010082406 peptide permease Proteins 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000029553 photosynthesis Effects 0.000 description 2
- 238000010672 photosynthesis Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010080502 preprolactin Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 150000003147 proline derivatives Chemical class 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 108010068698 spleen exonuclease Proteins 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- KNWCDYSKJSREAQ-VKHMYHEASA-N (2s)-1,3-oxazolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1NCCO1 KNWCDYSKJSREAQ-VKHMYHEASA-N 0.000 description 1
- FQRURPFZTFUXEZ-MRVPVSSYSA-N (2s)-2,3,3,3-tetrafluoro-2-(n-fluoroanilino)propanoic acid Chemical compound OC(=O)[C@](F)(C(F)(F)F)N(F)C1=CC=CC=C1 FQRURPFZTFUXEZ-MRVPVSSYSA-N 0.000 description 1
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 description 1
- RWBLYSWJMSKZAL-UCORVYFPSA-N (2s,3s)-2,5-diamino-3-methyl-5-oxopentanoic acid Chemical class NC(=O)C[C@H](C)[C@H](N)C(O)=O RWBLYSWJMSKZAL-UCORVYFPSA-N 0.000 description 1
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000981 3-amino-3-oxopropyl group Chemical group [H]C([*])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- XWHHYOYVRVGJJY-UHFFFAOYSA-N 4-fluorophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-UHFFFAOYSA-N 0.000 description 1
- XFGVJLGVINCWDP-UHFFFAOYSA-N 5,5,5-trifluoroleucine Chemical compound FC(F)(F)C(C)CC(N)C(O)=O XFGVJLGVINCWDP-UHFFFAOYSA-N 0.000 description 1
- HYQXNCDBSALQLB-UHFFFAOYSA-N 9-bromo-9-phenylfluorene Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(Br)C1=CC=CC=C1 HYQXNCDBSALQLB-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 102000006534 Amino Acid Isomerases Human genes 0.000 description 1
- 108010008830 Amino Acid Isomerases Proteins 0.000 description 1
- 108050005273 Amino acid transporters Proteins 0.000 description 1
- 102000034263 Amino acid transporters Human genes 0.000 description 1
- OZDNDGXASTWERN-CTNGQTDRSA-N Apovincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-CTNGQTDRSA-N 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 229930195713 D-glutamate Natural products 0.000 description 1
- YAHZABJORDUQGO-NQXXGFSBSA-N D-ribulose 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)C(=O)COP(O)(O)=O YAHZABJORDUQGO-NQXXGFSBSA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 101710196859 Dipeptide-binding protein Proteins 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 101000925646 Enterobacteria phage T4 Endolysin Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100324575 Escherichia coli O78:H11 (strain H10407 / ETEC) gspS2 gene Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 108010054320 Lignin peroxidase Proteins 0.000 description 1
- 101710155614 Ligninase A Proteins 0.000 description 1
- 101710155621 Ligninase B Proteins 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000203353 Methanococcus Species 0.000 description 1
- 108010003060 Methionine-tRNA ligase Proteins 0.000 description 1
- 102000000362 Methionyl-tRNA synthetases Human genes 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 101100278853 Mus musculus Dhfr gene Proteins 0.000 description 1
- 101100462972 Mus musculus Pcdh8 gene Proteins 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 1
- 108010033272 Nitrilase Proteins 0.000 description 1
- 108010024026 Nitrile hydratase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- PEMUHKUIQHFMTH-UHFFFAOYSA-N P-Bromo-DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-UHFFFAOYSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 102000002798 Phenylalanine-tRNA Ligase Human genes 0.000 description 1
- 108010004478 Phenylalanine-tRNA Ligase Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 108010051611 Signal Recognition Particle Proteins 0.000 description 1
- 102000013598 Signal recognition particle Human genes 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000007124 Tachykinin Receptors Human genes 0.000 description 1
- 108010072901 Tachykinin Receptors Proteins 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000018378 Tyrosine-tRNA ligase Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 108700040099 Xylose isomerases Proteins 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940067621 aminobutyrate Drugs 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- OZDNDGXASTWERN-UHFFFAOYSA-N apovincamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 101150079521 aspS gene Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000000723 chemosensory effect Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 101150099953 ilvE gene Proteins 0.000 description 1
- 150000007976 iminium ions Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003262 industrial enzyme Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- XHTJLMYQJHCUPE-UHFFFAOYSA-N phosphanylphosphonic acid Chemical compound OP(O)(P)=O XHTJLMYQJHCUPE-UHFFFAOYSA-N 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000001402 polyadenylating effect Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- QSHGUCSTWRSQAF-FJSLEGQWSA-N s-peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C1=CC=C(OS(O)(=O)=O)C=C1 QSHGUCSTWRSQAF-FJSLEGQWSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 229950001139 timonacic Drugs 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- YLJLTSVBCXYTQK-VKHMYHEASA-N trifluoro-L-methionine Chemical compound OC(=O)[C@@H](N)CCSC(F)(F)F YLJLTSVBCXYTQK-VKHMYHEASA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/005—Amino acids other than alpha- or beta amino acids, e.g. gamma amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28503001P | 2001-04-19 | 2001-04-19 | |
| US35551402P | 2002-02-06 | 2002-02-06 | |
| PCT/US2002/012465 WO2002085923A2 (en) | 2001-04-19 | 2002-04-19 | In vivo incorporation of unnatural amino acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03009563A true MXPA03009563A (es) | 2004-12-06 |
Family
ID=26962950
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03009563A MXPA03009563A (es) | 2001-04-19 | 2002-04-19 | Incorporacion in vivo de aminoacidos no naturales. |
| MXPA03009566A MXPA03009566A (es) | 2001-04-19 | 2002-04-19 | Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03009566A MXPA03009566A (es) | 2001-04-19 | 2002-04-19 | Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales. |
Country Status (11)
| Country | Link |
|---|---|
| US (19) | US7083970B2 (https=) |
| EP (5) | EP2796546B1 (https=) |
| JP (7) | JP2004537984A (https=) |
| AU (2) | AU2002303431C1 (https=) |
| CA (2) | CA2444098C (https=) |
| DK (4) | DK1490483T3 (https=) |
| ES (1) | ES2464532T3 (https=) |
| HK (1) | HK1203558A1 (https=) |
| IL (7) | IL158419A0 (https=) |
| MX (2) | MXPA03009563A (https=) |
| WO (2) | WO2002085923A2 (https=) |
Families Citing this family (442)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085923A2 (en) * | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| WO2003033521A1 (en) | 2001-10-16 | 2003-04-24 | Massachusetts Institute Of Technology | Inppressor trna system in mammalian cells for the introduction of unnatural amino acids in polypeptides. |
| US20030148391A1 (en) * | 2002-01-24 | 2003-08-07 | Salafsky Joshua S. | Method using a nonlinear optical technique for detection of interactions involving a conformational change |
| US7112435B1 (en) | 2002-08-07 | 2006-09-26 | Ambit Biosciences Corporation | Uncoupling of DNA insert propagation and expression of protein for phage display |
| US20040038273A1 (en) * | 2002-06-17 | 2004-02-26 | Whitehead Institute For Biomedical Research | Bifunctional tRNA for in vitro selection |
| AU2003252153A1 (en) * | 2002-07-25 | 2004-02-16 | Mds Proteomics Inc. | Improved systems and methods for analysis of protein post-translational modification |
| US7897381B2 (en) * | 2002-08-07 | 2011-03-01 | Ambit Biosciences Corporation | Uncoupling of DNA insert propagation and expression of protein for phage display |
| US7833741B2 (en) * | 2002-08-07 | 2010-11-16 | Ambit Biosciences Corporation | Uncoupling of DNA insert propagation and expression of protein for phage display |
| US7563600B2 (en) | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
| JP4444113B2 (ja) | 2002-10-16 | 2010-03-31 | ザ スクリップス リサーチ インスティテュート | ケトアミノ酸の部位特異的蛋白質組込み方法 |
| MXPA05003978A (es) | 2002-10-16 | 2005-06-22 | Scripps Research Inst | Sintesis de glicoproteinas. |
| CA2508939A1 (en) | 2002-12-22 | 2004-07-15 | The Scripps Research Institute | Protein arrays |
| WO2004060403A2 (en) | 2003-01-06 | 2004-07-22 | Angiochem Inc. | Aprotinin and anglos as carriers across the blood-brain barrier |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JP2006180701A (ja) * | 2003-02-10 | 2006-07-13 | Institute Of Physical & Chemical Research | チロシルｔＲＮＡ合成酵素の変異体及びその作製方法 |
| AU2013201487B2 (en) * | 2003-04-17 | 2014-09-18 | The Scripps Research Institute | Expanding the eukaryotic genetic code |
| JP5642916B2 (ja) | 2003-04-17 | 2014-12-17 | ザ スクリプス リサーチ インスティテュート | 真核遺伝コードの拡張 |
| WO2004110964A2 (en) * | 2003-06-16 | 2004-12-23 | Nuevolution A/S | Encoded molecules by translation (emt) |
| EP2410331B1 (en) | 2003-06-18 | 2015-09-23 | The Scripps Research Institute | Aminoacyl-tRNA synthetase for aminoacylation tRNA with unnatural amino acids |
| US20060160175A1 (en) * | 2003-07-07 | 2006-07-20 | The Scripps Research Institute | Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof |
| EP1649004A4 (en) * | 2003-07-07 | 2008-04-09 | Scripps Research Inst | COMPOSITIONS WITH PAIRS OF ORTHOGONAL LYSYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF |
| WO2005007624A2 (en) * | 2003-07-07 | 2005-01-27 | The Scripps Research Institute | Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof |
| EP1668114B1 (en) * | 2003-08-18 | 2009-11-04 | The Regents of the University of California | Polypeptide display libraries and methods of making and using thereof |
| PT1687401E (pt) | 2003-10-14 | 2013-02-26 | Scripps Research Inst | Incorporação de aminoácidos activos em oxidação-redução específica do local em proteínas |
| AU2004314710A1 (en) * | 2003-12-12 | 2005-08-11 | Conjugon, Inc. | Systems for tightly regulated gene expression |
| US7741071B2 (en) * | 2003-12-18 | 2010-06-22 | The Scripps Research Institute | Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells |
| BRPI0507169A (pt) | 2004-02-02 | 2007-06-26 | Ambrx Inc | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos |
| AU2005222788A1 (en) * | 2004-02-27 | 2005-09-29 | President And Fellows Of Harvard College | Polynucleotide synthesis |
| FR2868081A1 (fr) * | 2004-03-23 | 2005-09-30 | Libragen Sa | Methode d'identification de famille de voie metabolique par selection positive |
| US20050260711A1 (en) * | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| EP1757686A4 (en) * | 2004-04-09 | 2008-03-12 | Chugai Pharmaceutical Co Ltd | Cell death inducer |
| US20050287639A1 (en) | 2004-05-17 | 2005-12-29 | California Institute Of Technology | Methods of incorporating amino acid analogs into proteins |
| JP2008500050A (ja) * | 2004-05-25 | 2008-01-10 | ザ スクリップス リサーチ インスティテュート | 結晶構造決定のための重原子含有非天然アミノ酸の部位特異的蛋白質組込み |
| US20060008844A1 (en) * | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| US7632924B2 (en) * | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
| ZA200609926B (en) * | 2004-06-18 | 2009-02-25 | Ambrx Inc | Novel antigen-binding polypeptides and their uses |
| SI1771474T1 (sl) | 2004-07-20 | 2010-06-30 | Genentech Inc | Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba |
| WO2006091231A2 (en) * | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| AU2005286722B2 (en) * | 2004-09-21 | 2010-12-02 | The Scripps Research Institute | In vivo incorporation of alkynyl amino acids into proteins in eubacteria |
| US20080171317A1 (en) * | 2004-09-22 | 2008-07-17 | The Scripps Research Institute | Site-Specific Labeling of Proteins for Nmr Studies |
| JP2008523786A (ja) * | 2004-10-18 | 2008-07-10 | コドン デバイシズ インコーポレイテッド | 高忠実度合成ポリヌクレオチドのアセンブリ方法 |
| US20070122817A1 (en) * | 2005-02-28 | 2007-05-31 | George Church | Methods for assembly of high fidelity synthetic polynucleotides |
| JP2008516637A (ja) * | 2004-10-20 | 2008-05-22 | ザ スクリップス リサーチ インスティテュート | 真正細菌へのｎ−アセチルガラクトサミンアミノ酸のインビボ部位特異的組込み |
| CN101048506B (zh) | 2004-10-27 | 2013-06-26 | 斯克利普斯研究院 | 体内掺入非天然氨基酸的正交翻译组分 |
| AU2011204773B2 (en) * | 2004-10-27 | 2012-02-02 | The Scripps Research Institute | Orthogonal translation components for the in vivo incorporation of unnatural amino acids |
| WO2006050247A2 (en) | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| WO2006055898A2 (en) * | 2004-11-20 | 2006-05-26 | Massachusetts Institute Of Technology | Orthogonal suppressor trnas and aminoacyl-trna synthetases and uses thereof |
| US20090023139A1 (en) * | 2004-11-22 | 2009-01-22 | Kazuya Nishikawa | Method For Site-Specifically Introducing Non-Natural Amino Acid Into Protien Using Mitochondrial Protein and Method For Effectively Preparing Trna |
| AU2013205030B2 (en) * | 2004-12-22 | 2016-05-12 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| CN103520735B (zh) * | 2004-12-22 | 2015-11-25 | Ambrx公司 | 包含非天然编码的氨基酸的人生长激素配方 |
| EP1836298B1 (en) | 2004-12-22 | 2012-01-18 | Ambrx, Inc. | COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF |
| BRPI0519430A2 (pt) * | 2004-12-22 | 2009-02-10 | Ambrx Inc | hormânio do crescimento humano modificado |
| EP2399893B1 (en) | 2004-12-22 | 2018-08-15 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| EP1836316A4 (en) * | 2004-12-22 | 2009-07-22 | Ambrx Inc | PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2006107813A2 (en) * | 2005-04-05 | 2006-10-12 | Yale University | Site specific incorporation of phosphoserine into polypeptides using phosphoseryl-trna synthetase |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| WO2006122224A1 (en) * | 2005-05-11 | 2006-11-16 | Wayne State University | Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in pseudomonas aeruginosa |
| EP1891092A4 (en) * | 2005-06-03 | 2011-12-21 | Ambrx Inc | INSTALLATION OF NATURALLY CODED AMINO ACIDS IN PROTEINS |
| AU2006255122B2 (en) * | 2005-06-03 | 2010-10-21 | Ambrx, Inc. | Improved human interferon molecules and their uses |
| KR101367544B1 (ko) * | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용 |
| WO2007005053A1 (en) * | 2005-06-30 | 2007-01-11 | Codon Devices, Inc. | Hierarchical assembly methods for genome engineering |
| ES2744225T3 (es) | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| JP5213706B2 (ja) * | 2005-07-15 | 2013-06-19 | メディカル リサーチ カウンシル | 直交性リボソームｍＲＮＡペアに関する組成物および方法 |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AU2005335491B2 (en) | 2005-08-18 | 2010-11-25 | Ambrx, Inc. | Compositions of tRNA and uses thereof |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| BRPI0617191A2 (pt) * | 2005-10-12 | 2011-07-19 | Scripps Research Inst | modificação pós-traducional de polipeptìdeos expressos em fagos |
| DK2339014T3 (en) | 2005-11-16 | 2015-07-20 | Ambrx Inc | Methods and compositions comprising non-natural amino acids |
| WO2007070659A2 (en) * | 2005-12-14 | 2007-06-21 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| CA2633524A1 (en) | 2005-12-22 | 2007-07-05 | Pacific Biosciences Of California, Inc. | Polymerases for nucleotide analogue incorporation |
| CN105085313A (zh) * | 2005-12-30 | 2015-11-25 | Ambrx公司 | 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途 |
| AU2007215566A1 (en) * | 2006-01-19 | 2007-08-23 | Ambrx, Inc. | Non-natural amino acid polypeptides having modulated immunogenicity |
| US20070178554A1 (en) * | 2006-02-01 | 2007-08-02 | Nima Shiva | Orthogonal Aminoacyl Synthetase-tRNA Pairs for Incorporating Unnatural Amino Acids Into Proteins |
| WO2007090198A2 (en) * | 2006-02-01 | 2007-08-09 | Encode Bio, Inc. | Fluorescent assays using orthogonal trna - aminoacyl synthetase pairs |
| WO2007092475A2 (en) * | 2006-02-06 | 2007-08-16 | Franklin And Marshall College | Site-specific incorporation of fluorinated amino acids into proteins |
| AU2007224019A1 (en) | 2006-03-03 | 2007-09-13 | California Institute Of Technology | Site-specific incorporation of amino acids into molecules |
| KR20080106430A (ko) * | 2006-03-09 | 2008-12-05 | 더 스크립스 리서치 인스티튜트 | 진정 세균 숙주 세포 내에서의 직교형 번역 성분의 발현을 위한 시스템 |
| WO2007109035A2 (en) | 2006-03-16 | 2007-09-27 | The Scripps Research Institute | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine |
| US20080096819A1 (en) | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
| JP5313129B2 (ja) | 2006-05-02 | 2013-10-09 | アロザイン， インコーポレイテッド | 非天然アミノ酸置換ポリペプチド |
| AU2007267950B2 (en) | 2006-05-23 | 2012-08-16 | The Scripps Research Institute | Genetically encoded fluorescent coumarin amino acids |
| KR101459789B1 (ko) * | 2006-06-09 | 2014-11-07 | 노파르티스 아게 | 안정화된 인슐린-유사 성장 인자 폴리펩티드 |
| WO2008001947A1 (en) * | 2006-06-28 | 2008-01-03 | Riken | MUTANT SepRS, AND METHOD FOR SITE-SPECIFIC INTRODUCTION OF PHOSPHOSERINE INTO PROTEIN BY USING THE SAME |
| WO2008066583A2 (en) * | 2006-06-29 | 2008-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free synthesis of proteins containing unnatural amino acids |
| US20100150927A1 (en) * | 2006-07-13 | 2010-06-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducer |
| AU2013202770B2 (en) * | 2006-09-08 | 2015-08-20 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| EP2064333B1 (en) | 2006-09-08 | 2014-02-26 | Ambrx, Inc. | Suppressor trna transcription in vertebrate cells |
| JP5399906B2 (ja) | 2006-09-08 | 2014-01-29 | アンブルックス，インコーポレイテッド | 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ |
| JP2010502221A (ja) * | 2006-09-08 | 2010-01-28 | アンブルックス，インコーポレイテッド | 脊椎動物細胞による非天然アミノ酸の部位特異的組み込み |
| AU2012203737B2 (en) * | 2006-09-08 | 2014-06-19 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
| CN106008699A (zh) | 2006-09-08 | 2016-10-12 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| JP5385143B2 (ja) * | 2006-09-21 | 2014-01-08 | ザ スクリプス リサーチ インスティチュート | 真正細菌における選択的に硫酸化された蛋白質の遺伝的にプログラムされた発現 |
| WO2008073184A2 (en) | 2006-10-18 | 2008-06-19 | The Scripps Research Institute | Genetic incorporation of unnatural amino acids into proteins in mammalian cells |
| WO2008065372A2 (en) | 2006-11-28 | 2008-06-05 | Nautilus Biotech, S.A. | Modified erythropoietin polypeptides and uses thereof for treatment |
| EP1936340A1 (en) * | 2006-12-21 | 2008-06-25 | Koninklijke Philips Electronics N.V. | Sub wavelength aperture |
| EP2112928A4 (en) * | 2007-02-22 | 2014-01-08 | Univ Utah Res Found | SYNTHESIS OF NOVEL XYLOSIDES AND ITS POSSIBLE USES |
| CL2008000719A1 (es) * | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| CN107501407B (zh) | 2007-03-30 | 2022-03-18 | Ambrx公司 | 经修饰fgf-21多肽和其用途 |
| US8183037B2 (en) * | 2007-04-13 | 2012-05-22 | The Salk Institute For Biological Studies | Methods of genetically encoding unnatural amino acids in eukaryotic cells using orthogonal tRNA/synthetase pairs |
| US8114630B2 (en) * | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| WO2009036460A2 (en) * | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
| CA2702061A1 (en) * | 2007-10-08 | 2009-04-16 | Synthetic Genomics, Inc. | System and method for producing synthetic microorganisms capable of translating proteins containing non-standard amino acids |
| US8673591B2 (en) | 2007-10-25 | 2014-03-18 | The Scripps Research Institute | Genetic incorporation of 3-aminotyrosine into reductases |
| JP5513398B2 (ja) * | 2007-11-02 | 2014-06-04 | ザ スクリプス リサーチ インスティチュート | 非天然アミノ酸を含有する蛋白質を使用する指向的進化 |
| BRPI0820327A2 (pt) | 2007-11-02 | 2020-10-06 | Novartis Ag | moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6) |
| WO2009059056A2 (en) * | 2007-11-02 | 2009-05-07 | The Scripps Research Institute | A genetically encoded boronate amino acid |
| WO2009064416A2 (en) * | 2007-11-15 | 2009-05-22 | The Scripps Research Institute | Genetic incorporation of an alpha-hydroxy acid into proteins to generate ester backbone linkages at defined sites |
| MX2010005317A (es) * | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| CN101939410A (zh) * | 2007-12-11 | 2011-01-05 | 斯克利普斯研究院 | 甲基营养酵母菌巴斯德毕赤酵母中的体内非天然氨基酸表达 |
| CN104651381A (zh) | 2008-01-03 | 2015-05-27 | 巴斯夫酶有限责任公司 | 转移酶和氧化还原酶、编码它们的核酸以及其制备和应用方法 |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| MX344166B (es) | 2008-02-08 | 2016-12-07 | Ambrx Inc | Leptina-polipeptidos modificados y sus usos. |
| EP2249865A4 (en) * | 2008-02-08 | 2012-04-04 | Scripps Research Inst | BREAKING IMMUNOLOGICAL TOLERANCE WITH A GENETICALLY ENCODED UNNATURAL AMINO ACID |
| US20110015345A1 (en) * | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
| WO2009117726A2 (en) * | 2008-03-21 | 2009-09-24 | The Regents Of The University Of California | High-sensitive fluorescent energy transfer assay using fluorescent amino acids and fluoresent proteins |
| EP2604279A1 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
| EP2942404B1 (en) | 2008-03-31 | 2016-11-23 | Pacific Biosciences of California, Inc. | Generation of modified polymerases for improved accuracy in single molecule sequencing |
| EA201001734A1 (ru) | 2008-05-02 | 2011-10-31 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| WO2009155513A2 (en) | 2008-06-20 | 2009-12-23 | Novartis Ag | Immunoglobulins with reduced aggregation |
| CN102159708B (zh) | 2008-06-26 | 2016-08-31 | Atyr医药公司 | 包含具有非常规生物活性的甘氨酰-tRNA合成酶的组合物和方法 |
| AU2009270405B2 (en) * | 2008-06-30 | 2014-06-05 | Esbatech, An Alcon Biomedical Research Unit Llc | Functionalized polypeptides |
| EP2769711A1 (en) * | 2008-07-10 | 2014-08-27 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods and Compositions for Enhanced Delivery of Macromolecules |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| CN102159230A (zh) | 2008-07-23 | 2011-08-17 | Ambrx公司 | 经修饰的牛g-csf多肽和其用途 |
| US9182406B2 (en) * | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
| US20110195900A1 (en) * | 2008-08-19 | 2011-08-11 | Ferring B.V. | Peptidic pth receptor agonists |
| BR122012024318A2 (pt) | 2008-09-26 | 2019-07-30 | Ambrx, Inc. | Polipeptídeos modificados de eritropoetina animal e seus usos |
| AU2009296267B2 (en) | 2008-09-26 | 2013-10-31 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| WO2010048582A1 (en) | 2008-10-24 | 2010-04-29 | Irm Llc | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8609383B2 (en) | 2008-12-10 | 2013-12-17 | The Scripps Research Institute | Production of carrier-peptide conjugates using chemically reactive unnatural amino acids |
| US20090197339A1 (en) * | 2008-12-10 | 2009-08-06 | The Scripps Research Institute | In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris |
| US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| JP5789515B2 (ja) * | 2008-12-19 | 2015-10-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン類似体 |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2010080605A1 (en) * | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
| WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| EP2403864B1 (en) | 2009-02-27 | 2015-08-12 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
| US20100310576A1 (en) * | 2009-03-31 | 2010-12-09 | Adams Ryan A | COMPOSITIONS AND METHODS COMPRISING ASPARTYL-tRNA SYNTHETASES HAVING NON-CANONICAL BIOLOGICAL ACTIVITIES |
| MX2011011023A (es) | 2009-04-20 | 2012-01-20 | Angiochem Inc | Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2. |
| AU2010247938B2 (en) | 2009-05-11 | 2016-02-18 | Pelican Technology Holdings, Inc. | Production of recombinant proteins utilizing non-antibiotic selection methods and the incorporation of non-natural amino acids therein |
| MX2011012665A (es) | 2009-06-04 | 2012-03-07 | Novartis Ag | Metodos para identificacion de sitios para conjugacion de igg. |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| US20110054019A1 (en) * | 2009-09-01 | 2011-03-03 | Pedro Anastacio Serrano-Ojeda | Cancer Starvation Therapy |
| US10292956B2 (en) | 2009-09-01 | 2019-05-21 | Serbig Pharmaceutics Corp. | Cancer starvation therapy |
| EP2311947A1 (en) * | 2009-10-14 | 2011-04-20 | Ludwig-Maximilians-Universität München | Protein synthesis via click chemistry |
| WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
| WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
| WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| US20120282276A1 (en) | 2009-11-05 | 2012-11-08 | The Regents Of The University Of Michigan | Biomarkers predictive of progression of fibrosis |
| US9051593B2 (en) | 2009-12-21 | 2015-06-09 | Trustees Of Dartmouth College | Recombinant prokaryotes and use thereof for production of O-glycosylated proteins |
| MX349301B (es) | 2009-12-21 | 2017-07-21 | Ambrx Inc | Polipéptidos de somatotropina bovina modificados y sus usos. |
| BR112012015597A2 (pt) | 2009-12-21 | 2017-01-31 | Ambrx Inc | peptídeos de somatotropina suínos modificados e seus usos |
| AU2011210840B2 (en) | 2010-01-27 | 2014-12-11 | Massachusetts Institute Of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
| WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
| US20120296403A1 (en) | 2010-02-10 | 2012-11-22 | Novartis Ag | Methods and compounds for muscle growth |
| US8674064B2 (en) * | 2010-03-03 | 2014-03-18 | Onkologix Ltd | Immunogenic compositions against human progastrin peptides |
| US8464858B2 (en) | 2010-03-12 | 2013-06-18 | Cabin Creek Inc. | Conveyor belt scraper and system for the same |
| WO2011119771A2 (en) * | 2010-03-23 | 2011-09-29 | The Salk Institute For Biological Studies | Methods and compositions for detecting protein modifications |
| CA2797093C (en) | 2010-04-26 | 2019-10-29 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
| EP2563381B1 (en) | 2010-04-27 | 2017-08-09 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
| AU2011248521B2 (en) | 2010-04-27 | 2017-03-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl tRNA synthetases |
| CN103097524B (zh) | 2010-04-28 | 2016-08-03 | Atyr医药公司 | 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CA2797374C (en) | 2010-04-29 | 2021-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
| EP2563383B1 (en) | 2010-04-29 | 2017-03-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
| ES2668207T3 (es) | 2010-05-03 | 2018-05-17 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas |
| AU2011248227B2 (en) | 2010-05-03 | 2016-12-01 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| CN103096925A (zh) | 2010-05-03 | 2013-05-08 | Atyr医药公司 | 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| EP2566516B1 (en) | 2010-05-03 | 2019-07-03 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases |
| JP6008844B2 (ja) | 2010-05-04 | 2016-10-19 | エータイアー ファーマ， インコーポレイテッド | ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| CN103096909A (zh) | 2010-05-04 | 2013-05-08 | Atyr医药公司 | 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| EP2568996B1 (en) | 2010-05-14 | 2017-10-04 | aTyr Pharma, Inc. | Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| US9034598B2 (en) | 2010-05-17 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
| CN103096913B (zh) | 2010-05-27 | 2017-07-18 | Atyr 医药公司 | 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CA2800281C (en) | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| JP5969469B2 (ja) | 2010-06-16 | 2016-08-17 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト |
| WO2011158895A1 (ja) * | 2010-06-16 | 2011-12-22 | 独立行政法人理化学研究所 | 非天然タンパク質製造用の組換え細菌の作製方法、及びその利用 |
| EP2588126A4 (en) | 2010-06-24 | 2015-07-08 | Univ Indiana Res & Tech Corp | AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS |
| EP2585102B1 (en) | 2010-06-24 | 2015-05-06 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
| KR20130102534A (ko) | 2010-07-12 | 2013-09-17 | 에이티와이알 파마, 인코포레이티드 | 히스티딜trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견 |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| KR20180059575A (ko) * | 2010-07-12 | 2018-06-04 | 에이티와이알 파마, 인코포레이티드 | 아스파르틸trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견 |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| EA030886B1 (ru) | 2010-08-17 | 2018-10-31 | Амбркс, Инк. | Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение |
| CN103108650A (zh) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| EP2640745B1 (en) | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| CN103118696B (zh) * | 2010-10-06 | 2020-02-14 | Atyr 医药公司 | 与色氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物 |
| US9090928B2 (en) | 2010-10-07 | 2015-07-28 | Yale University | Site-specific incorporation of phosphoserine into proteins in Escherichia coli |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| WO2012097333A2 (en) | 2011-01-14 | 2012-07-19 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
| ES2661095T3 (es) | 2011-02-03 | 2018-03-27 | European Molecular Biology Laboratory | Aminoácidos no naturales que comprenden un grupo análogo de ciclooctinilo o trans-ciclooctenilo y usos de los mismos |
| GB2503604B (en) | 2011-03-21 | 2020-04-22 | Biodesy Llc | Classification of kinase inhibitors using second harmonic optical techniques |
| EP2694083A2 (en) | 2011-04-01 | 2014-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders |
| DK2694095T3 (en) | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US10876142B2 (en) | 2011-07-11 | 2020-12-29 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| US11788111B2 (en) | 2011-07-11 | 2023-10-17 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| WO2013009868A1 (en) | 2011-07-11 | 2013-01-17 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| US10240158B2 (en) | 2011-07-11 | 2019-03-26 | Yale University | Compositions and methods for making selenocysteine containing polypeptides |
| CN102888387B (zh) * | 2011-07-21 | 2015-03-18 | 中国科学院生物物理研究所 | 3-氯代酪氨酸翻译系统及其应用 |
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| CN102925427B (zh) * | 2011-08-08 | 2014-01-22 | 中国科学院生物物理研究所 | 丙烯酰赖氨酸翻译系统及其应用 |
| US9714419B2 (en) | 2011-08-09 | 2017-07-25 | Atyr Pharma, Inc. | PEGylated tyrosyl-tRNA synthetase polypeptides |
| UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| WO2013086228A1 (en) * | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Pegylated aspartyl-trna synthetase polypeptides |
| WO2013086216A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Improved aspartyl-trna synthetases |
| BR112014015156A2 (pt) | 2011-12-20 | 2020-10-27 | Indiana University Research And Technology Corporation | análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira |
| TW202446781A (zh) | 2011-12-28 | 2024-12-01 | 日商中外製藥股份有限公司 | 胜肽化合物之製造方法 |
| CA2858613A1 (en) | 2011-12-29 | 2013-08-08 | Atyr Pharma, Inc. | Aspartyl-trna synthetase-fc conjugates |
| US9395358B2 (en) | 2012-02-05 | 2016-07-19 | Biodesy, Inc. | Methods for detecting allosteric modulators of protein |
| EP2814514B1 (en) | 2012-02-16 | 2017-09-13 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
| SG11201406769RA (en) | 2012-05-10 | 2014-11-27 | Massachusetts Inst Technology | Agents for influenza neutralization |
| CN108727466B (zh) | 2012-06-07 | 2023-04-28 | Ambrx公司 | 前列腺特异性膜抗原抗体药物结合物 |
| EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| KR102190832B1 (ko) | 2012-06-19 | 2020-12-15 | 암브룩스, 인코포레이티드 | 항cd70 항체 약물 컨쥬게이트 |
| WO2014004639A1 (en) | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| CN103571804B (zh) * | 2012-08-10 | 2015-08-12 | 中国科学院生物物理研究所 | 3-吡唑基酪氨酸翻译系统及其应用 |
| AU2013305744B2 (en) | 2012-08-22 | 2017-06-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered anthrax lethal toxin for targeted delivery |
| WO2014035364A2 (en) * | 2012-08-27 | 2014-03-06 | Empire Technology Development Llc | Gelatin alkyd peptides and uses thereof |
| EP2890402B1 (en) | 2012-08-31 | 2019-04-17 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
| EP2898085B1 (en) | 2012-09-24 | 2019-01-23 | MedImmune Limited | Cell lines |
| EP3395358B1 (en) | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
| CN102875733B (zh) * | 2012-10-25 | 2014-06-11 | 西安科技大学 | 具有仿细胞外层膜结构的纳米颗粒及其制备方法 |
| US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| PL2935320T3 (pl) | 2012-12-18 | 2020-03-31 | Novartis Ag | Stabilizowane polipeptydy insulinopodobnego czynnika wzrostu |
| CA2936092A1 (en) | 2013-01-23 | 2014-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized hepatitis b core polypeptide |
| WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9255255B2 (en) | 2013-03-04 | 2016-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Synthesis of linear and branched polymers of polypeptides through direct conjugation |
| UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| JP6538645B2 (ja) | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン‐インクレチン複合物 |
| WO2014145654A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Method for the site-specific covalent cross-linking of antibodies to surfaces |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| JP6574754B2 (ja) | 2013-03-19 | 2019-09-11 | ベイジン シェノゲン ファーマ グループ リミテッド | エストロゲン受容体関連疾患を処置するための抗体及び方法 |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| KR101568336B1 (ko) | 2013-07-02 | 2015-11-12 | 서강대학교산학협력단 | 목적 단백질의 돌연변이체를 생성하는 세포, 상기 세포의 제조 방법, 및 상기 세포를 이용한 목적 단백질의 돌연변이체의 제조 방법 |
| WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3021942A4 (en) | 2013-07-19 | 2017-04-19 | The Regents of The University of California | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake |
| KR20160031551A (ko) | 2013-07-25 | 2016-03-22 | 노파르티스 아게 | 심부전의 치료를 위한 시클릭 폴리펩티드 |
| HK1218252A1 (zh) | 2013-07-25 | 2017-02-10 | Novartis Ag | 合成apelin多肽之生物结合物 |
| AU2014305843B2 (en) | 2013-08-09 | 2019-08-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| WO2015031268A1 (en) | 2013-08-26 | 2015-03-05 | Arizona Board Of Regents On Behalf Of Arizona State University | High affinity synbodies for influenza |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| JP6661531B2 (ja) | 2013-10-10 | 2020-03-11 | シナジー ファーマシューティカルズ インコーポレイテッド | オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト |
| EP3055298B1 (en) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| EP3057605A1 (en) | 2013-10-18 | 2016-08-24 | Novartis AG | Methods of treating diabetes and related disorders |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3094977B1 (en) | 2014-01-14 | 2018-08-22 | European Molecular Biology Laboratory | Multiple cycloaddition reactions for labeling of molecules |
| WO2015120287A2 (en) * | 2014-02-06 | 2015-08-13 | Yale University | Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids |
| ES2913205T3 (es) | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| SG11201609706VA (en) | 2014-06-23 | 2017-01-27 | Novartis Ag | Site specific protein modifications |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US10316322B2 (en) | 2014-07-02 | 2019-06-11 | Sutro Biopharma, Inc. | High growth capacity auxotrophic Escherichia coli and methods of use |
| CA2954791C (en) | 2014-07-14 | 2025-11-18 | The Regents Of The University Of California | CRISPR/CAS TRANSCRIPTIONAL MODULATION |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| WO2016036916A1 (en) | 2014-09-03 | 2016-03-10 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| CN108271356A (zh) | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| JP6701208B2 (ja) | 2014-09-24 | 2020-05-27 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 脂質化アミド系インスリンプロドラッグ |
| US11408007B2 (en) | 2014-09-26 | 2022-08-09 | Yale University | Compositions and methods for biocontainment of microorganisms |
| CN114805532A (zh) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| US10335495B2 (en) | 2014-12-04 | 2019-07-02 | Celgene Corporation | Biomolecule conjugates |
| WO2016106286A1 (en) | 2014-12-23 | 2016-06-30 | Biodesy, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
| SE538541C2 (en) * | 2015-01-19 | 2016-09-13 | Fogelstrand Per | Method for preparing a biological sample for use in an immunolabeling process |
| CN107209176B (zh) | 2015-01-21 | 2020-08-14 | 克罗姆尼贡公司 | 免疫标记复合物的形成方法及用途 |
| MA41580A (fr) | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
| WO2016123578A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Protein delivery in primary hematopoietic cells |
| EP4166664A1 (en) | 2015-03-13 | 2023-04-19 | Chugai Seiyaku Kabushiki Kaisha | Modified aminoacyl-trna synthetase and use thereof |
| US10483262B2 (en) * | 2015-05-15 | 2019-11-19 | Taiwan Semiconductor Manufacturing Co., Ltd. | Dual nitride stressor for semiconductor device and method of manufacturing |
| WO2016199801A1 (ja) * | 2015-06-09 | 2016-12-15 | 国立研究開発法人産業技術総合研究所 | アミノ酸修飾核酸とその利用 |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| EP3331551B1 (en) | 2015-07-10 | 2021-06-23 | The Hong Kong University of Science and Technology | Compositions for use in treating neurodegenerative and neuroinflammatory conditions |
| WO2017062334A1 (en) | 2015-10-05 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| UA127495C2 (uk) | 2015-12-23 | 2023-09-13 | Амджен Інк. | Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить |
| CN106929482A (zh) * | 2015-12-31 | 2017-07-07 | 北京大学 | 定点突变的流感病毒、其活疫苗及其制备方法和应用 |
| US10653744B2 (en) | 2016-01-11 | 2020-05-19 | Bausch Health Ireland Limited | Formulations and methods for treating ulcerative colitis |
| WO2017132615A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
| JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール．ピー．シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
| EP3455628A4 (en) | 2016-05-09 | 2019-12-04 | Biodesy, Inc. | METHOD AND DEVICES FOR DETECTING INTERACTIONS OF PERIPHERAL MEMBRANE PROTEINS USING NONLINEAR OPTICAL TECHNIQUES |
| WO2017204729A1 (en) * | 2016-05-25 | 2017-11-30 | Fogelstrand Per | Method for preparing a biological sample for use in an immunolabeling process |
| AU2017283787B2 (en) | 2016-06-15 | 2020-09-17 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6) |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP3309260A1 (en) | 2016-10-14 | 2018-04-18 | European Molecular Biology Laboratory | Archaeal pyrrolysyl trna synthetases for orthogonal use |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| JP2020500020A (ja) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用 |
| KR20240045351A (ko) | 2016-11-14 | 2024-04-05 | 노파르티스 아게 | 연골 손상 및 관절염 치료 방법 및 조성물 |
| WO2018118997A2 (en) | 2016-12-19 | 2018-06-28 | Quantum-Si Incorporated | Polymerizing enzymes for sequencing reactions |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CN110366428B (zh) | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| IL313587A (en) | 2017-01-17 | 2024-08-01 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
| JP7187323B2 (ja) | 2017-01-31 | 2022-12-12 | 中外製薬株式会社 | 無細胞翻訳系におけるペプチドの合成方法 |
| US11730828B2 (en) | 2017-02-07 | 2023-08-22 | The Regents Of The University Of California | Gene therapy for haploinsufficiency |
| PE20191716A1 (es) | 2017-02-08 | 2019-12-05 | Bristol Myers Squibb Co | Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| EP3381932A1 (en) | 2017-03-28 | 2018-10-03 | Technische Universität Berlin | Modified mussel proteins, uses thereof and related compounds |
| CA3060514A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| PL3630977T3 (pl) | 2017-06-02 | 2024-06-24 | Ambrx, Inc. | Sposoby i kompozycje promujące produkcję białek zawierających nienaturalne aminokwasy |
| KR20250007021A (ko) | 2017-06-09 | 2025-01-13 | 추가이 세이야쿠 가부시키가이샤 | N-치환 아미노산을 포함하는 펩타이드의 합성 방법 |
| EA201992502A1 (ru) | 2017-06-20 | 2020-04-22 | Эмджен Инк. | Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1 |
| EP3642238A1 (en) | 2017-06-21 | 2020-04-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins |
| JP7325341B2 (ja) * | 2017-07-11 | 2023-08-14 | シンソークス，インク． | 非天然ヌクレオチドの組み込み及びその方法 |
| KR101956042B1 (ko) * | 2017-07-13 | 2019-03-08 | 서강대학교산학협력단 | 표적 단백질 내 l-디하이드록시페닐알라닌의 도입 방법 |
| WO2019023316A1 (en) | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| JP2020534352A (ja) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ，インコーポレーテッド | コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法 |
| KR20250035037A (ko) | 2017-09-18 | 2025-03-11 | 서트로 바이오파마, 인크. | 항-엽산 수용체 알파 항체 접합체 및 이의 용도 |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019117274A1 (ja) | 2017-12-15 | 2019-06-20 | 中外製薬株式会社 | ペプチドの製造方法、及び塩基の処理方法 |
| US12404512B2 (en) | 2018-05-01 | 2025-09-02 | Ambrx, Inc. | Method for optimizing antibody expression |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2019237119A1 (en) | 2018-06-08 | 2019-12-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New compositions and detection methods for onchocerca volvulus infection |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| CN112673109A (zh) * | 2018-09-07 | 2021-04-16 | 免疫医疗有限责任公司 | 细胞选择方法 |
| CA3111576A1 (en) | 2018-09-11 | 2020-03-19 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| JP2022500454A (ja) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体抗体コンジュゲートによる併用療法 |
| JP2022512746A (ja) | 2018-10-19 | 2022-02-07 | アンブルックス，インコーポレイテッド | インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US11325978B2 (en) | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
| EP3878836B1 (en) | 2018-11-07 | 2025-07-23 | Chugai Seiyaku Kabushiki Kaisha | O-substituted serine derivative production method |
| WO2020111238A1 (ja) | 2018-11-30 | 2020-06-04 | 中外製薬株式会社 | ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| CA3128081A1 (en) | 2019-02-12 | 2020-08-20 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-tlr agonist conjugates |
| EP3696189A1 (en) | 2019-02-14 | 2020-08-19 | European Molecular Biology Laboratory | Means and methods for preparing engineered target proteins by genetic code expansion in a target protein selective manner |
| JP7495420B2 (ja) | 2019-02-20 | 2024-06-04 | ノヴォ ノルディスク アー／エス | アミノアシル－ｔＲＮＡ合成酵素およびこの使用 |
| US12371817B2 (en) | 2019-03-04 | 2025-07-29 | The Texas A&M University System | Methods of making and utilizing amber-obligated phage display libraries |
| EP3939962A4 (en) | 2019-03-15 | 2022-12-28 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR PREPARING AN AROMATIC AMINO ACID DERIVATIVE |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020227105A1 (en) | 2019-05-03 | 2020-11-12 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
| US12258304B2 (en) | 2019-05-20 | 2025-03-25 | Albert Einstein College Of Medicine | Compounds and methods for treatment of bacterial infections |
| EP3980057A1 (en) | 2019-06-04 | 2022-04-13 | Institut Curie | Methods of producing shiga toxin b-subunit (stxb) monomers and oligomers, and uses thereof |
| US12139708B2 (en) | 2019-06-07 | 2024-11-12 | Massachusetts Institute Of Technology | Frameshift suppressor tRNA compositions and methods of use |
| JP7706210B2 (ja) | 2019-06-10 | 2025-07-11 | ストロ バイオファーマ インコーポレーテッド | ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート |
| CN114746420A (zh) | 2019-06-17 | 2022-07-12 | 苏特罗生物制药公司 | 用于癌症治疗和诊断的作为Toll样受体（TLR）7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物 |
| US11959105B2 (en) | 2019-06-28 | 2024-04-16 | Quantum-Si Incorporated | Polymerizing enzymes for sequencing reactions |
| KR20220076510A (ko) | 2019-10-08 | 2022-06-08 | 트러스티스 오브 보스톤 칼리지 | 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법 |
| TW202128996A (zh) * | 2019-10-10 | 2021-08-01 | 美商史基普研究協會 | 用於活體內合成非天然多肽的組合物及方法 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20230279378A1 (en) * | 2019-10-15 | 2023-09-07 | Trustees Of Boston College | Chimeric thermostable aminoacyl-trna synthetase for enhanced unnatural amino acid incorporation |
| US11149280B2 (en) | 2019-10-29 | 2021-10-19 | Yale University | Engineering organisms resistant to viruses and horizontally transferred genetic elements |
| CA3157470A1 (en) * | 2019-11-05 | 2021-05-14 | Neil Butler | Biosynthesis of para-nitro-l-phenylalanine |
| BR112022007535A2 (pt) | 2019-11-07 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Composto peptídico cíclico tendo ação inibitória de kras |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| JP7813706B2 (ja) | 2020-01-03 | 2026-02-13 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 歯周の健康を促進するために局所投与されるｔｎａｐ |
| CN113728013B (zh) | 2020-01-11 | 2022-06-14 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| EP4107258A4 (en) * | 2020-02-20 | 2024-04-17 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | MUTANT AMINOACYL-ARNT SYNTHETASES |
| EP3868882A1 (en) | 2020-02-21 | 2021-08-25 | European Molecular Biology Laboratory | Archaeal pyrrolysyl trna synthetases for orthogonal use |
| US20230095053A1 (en) | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
| EP4117732A1 (en) | 2020-03-11 | 2023-01-18 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
| CN111302975A (zh) * | 2020-03-30 | 2020-06-19 | 滨海吉尔多肽有限公司 | 一种n-叔丁氧羰基-o-烯丙基-l-酪氨酸的制备方法 |
| PE20231648A1 (es) | 2020-04-22 | 2023-10-17 | Merck Sharp And Dohme Llc | CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO |
| US12351850B2 (en) | 2020-04-30 | 2025-07-08 | Sutro Biopharma, Inc. | Methods of producing full-length antibodies using E. coli |
| AR122020A1 (es) | 2020-05-05 | 2022-08-03 | Genentech Inc | Sistemas y métodos para la conjugación específica de sitio de proteínas mediada por tirosinasa |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| CN115835904A (zh) | 2020-05-22 | 2023-03-21 | 武田药品工业有限公司 | 用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法 |
| JP2023538071A (ja) | 2020-08-20 | 2023-09-06 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用 |
| US20220089690A1 (en) * | 2020-09-14 | 2022-03-24 | Sutro Biopharma, Inc. | Method for large scale production of antibodies using a cell-free protein synthesis system |
| CN114729060B (zh) | 2020-09-30 | 2022-11-25 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
| CA3213805A1 (en) | 2021-04-03 | 2022-10-06 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
| US20230016731A1 (en) * | 2021-05-21 | 2023-01-19 | The Regents Of The University Of California | Affinity purification sequencing |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| EP4366781A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
| US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| WO2023281480A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| US12606598B2 (en) | 2021-07-12 | 2026-04-21 | Bactoclear Holdings PTE, Ltd. | Chimeric klebicins |
| US20250327057A1 (en) | 2021-09-06 | 2025-10-23 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
| JP2024533596A (ja) * | 2021-09-17 | 2024-09-12 | アブサイ コーポレイション | トランスファーｒｎａの組成、及び非標準アミノ酸を含むタンパク質の生産における使用 |
| US20240384267A1 (en) | 2021-09-20 | 2024-11-21 | The Broad Institute, Inc. | Compositions and methods for multiplex decoding of quadruplet codons |
| CA3234552A1 (en) | 2021-10-20 | 2023-04-27 | Synthekine, Inc. | Heterodimeric fc cytokines and uses thereof |
| WO2023081167A2 (en) | 2021-11-02 | 2023-05-11 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
| WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| DK4186529T3 (da) | 2021-11-25 | 2025-08-25 | Veraxa Biotech Gmbh | Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse |
| US20250135011A1 (en) | 2021-12-08 | 2025-05-01 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
| US20250092106A1 (en) | 2022-01-25 | 2025-03-20 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| WO2023161857A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
| EP4323413A4 (en) | 2022-03-30 | 2025-10-15 | Beijing Ql Biopharmaceutical Co Ltd | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF |
| CA3259758A1 (en) | 2022-06-30 | 2024-01-04 | Sutro Biopharma, Inc. | Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates |
| CN116376851A (zh) * | 2022-08-25 | 2023-07-04 | 凯莱英医药集团（天津）股份有限公司 | 氨酰tRNA合酶突变体及其应用 |
| NL2033185B1 (en) | 2022-09-29 | 2024-04-08 | Stichting Vu | Compounds for rna stabilisation and delivery |
| WO2024077277A1 (en) | 2022-10-07 | 2024-04-11 | Ambrx, Inc. | Drug linkers and antibody conjugates thereof |
| WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
| WO2024141087A1 (zh) * | 2022-12-31 | 2024-07-04 | 康码（上海）生物科技有限公司 | 一种用于插入非天然氨基酸的体外无细胞蛋白质合成体系、方法及应用 |
| US20240376170A1 (en) | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| JP2026504093A (ja) | 2023-01-16 | 2026-02-03 | アンブレツクス・インコーポレイテツド | 抗ｃｄ７０抗体薬物コンジュゲート |
| WO2024178310A1 (en) | 2023-02-23 | 2024-08-29 | Ambrx, Inc. | Trop2-directed antibody-drug conjugates and uses thereof |
| EP4689127A1 (en) | 2023-04-03 | 2026-02-11 | Sutro Biopharma, Inc. | Rf1 ko e. coli strains |
| WO2024241086A1 (en) | 2023-05-24 | 2024-11-28 | Ambrx, Inc. | Pegylated bovine interferon lambda and methods of use thereof |
| KR20260046464A (ko) | 2023-07-27 | 2026-04-07 | 베락사 바이오테크 게엠베하 | 친수성 트랜스-시클로옥텐(hyTCO) 화합물, 이를 포함하는 구조체 및 접합체 |
| AU2024329469A1 (en) | 2023-08-22 | 2026-04-09 | Ambrx, Inc. | Anti-psma adc conjugate compositions and methods of use thereof |
| WO2025041102A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| AU2024358957A1 (en) | 2023-10-13 | 2026-04-02 | Sutro Biopharma, Inc. | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates |
| WO2025080711A1 (en) | 2023-10-13 | 2025-04-17 | Sutro Biopharma, Inc. | Dual payload antibody drug conjugates |
| WO2025176699A1 (en) | 2024-02-20 | 2025-08-28 | LenioBio GmbH | A system and method for cell-free unnatural amino acid incorporation |
| WO2025184315A1 (en) | 2024-02-29 | 2025-09-04 | Amgen Inc. | Glucagon receptor agonists, conjugated to glucose-dependent insulinotropic polypeptide antibodies |
| WO2025199030A1 (en) | 2024-03-18 | 2025-09-25 | Amgen Inc. | Glp-1 receptor agonists and their medical use |
| EP4644408A1 (en) | 2024-04-19 | 2025-11-05 | The Chinese University of Hong Kong Office of Research and Knowledge Transfer Services (ORKTS) | Polyethylenimine-modified cry proteins and their use |
| WO2025257694A1 (en) | 2024-06-10 | 2025-12-18 | Università Degli Studi Di Torino | Cell differentiation through multimodal tuning of gene expression |
| WO2025257695A1 (en) | 2024-06-10 | 2025-12-18 | Università Degli Studi Di Torino | Growth factor-free stem cell expansion and differentiation |
| WO2026043823A2 (en) | 2024-08-19 | 2026-02-26 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof |
| WO2026069134A1 (en) | 2024-09-26 | 2026-04-02 | Bright Peak Therapeutics Ag | Human therapy with il-18 immunocytokines |
| WO2026080688A1 (en) | 2024-10-09 | 2026-04-16 | Sutro Biopharma, Inc. | Dual mechanism of action payload antibody drug conjugates |
| WO2026080697A1 (en) | 2024-10-09 | 2026-04-16 | Sutro Biopharma, Inc. | Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5001065A (en) | 1987-05-27 | 1991-03-19 | Cetus Corporation | Human cell line and triomas, antibodies, and transformants derived therefrom |
| DE9115660U1 (de) * | 1991-12-18 | 1992-07-30 | Aventis Research & Technologies GmbH & Co KG, 65929 Frankfurt | L-Phenylalanyl-tRNA-Synthetase mit erweiterter Substratselektivität aus Mikroorganismen |
| CA2219136A1 (en) | 1995-04-24 | 1996-10-31 | Chromaxome Corp. | Methods for generating and screening novel metabolic pathways |
| US5958672A (en) | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
| US5756316A (en) | 1995-11-02 | 1998-05-26 | Genencor International, Inc. | Molecular cloning by multimerization of plasmids |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US5783431A (en) | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
| US6706504B1 (en) * | 1996-11-12 | 2004-03-16 | The Scripps Research Institute | Tissue type plasminogen activator (t-PA) variants: compositions and methods of use |
| WO2002085923A2 (en) * | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| DE10151556A1 (de) * | 2001-10-23 | 2003-04-30 | Bosch Gmbh Robert | Vorrichtung zum Öffnen und Schließen eines beweglichen Teils |
| ITTO20020441A1 (it) * | 2002-05-24 | 2003-11-24 | Telecom Italia Lab Spa | Metodo per determinare l'installazione di costo minimo per le apparecchiature di una rete fissa di telecomunicazione. |
| MXPA05003978A (es) * | 2002-10-16 | 2005-06-22 | Scripps Research Inst | Sintesis de glicoproteinas. |
| JP4444113B2 (ja) * | 2002-10-16 | 2010-03-31 | ザ スクリップス リサーチ インスティテュート | ケトアミノ酸の部位特異的蛋白質組込み方法 |
| CA2508939A1 (en) * | 2002-12-22 | 2004-07-15 | The Scripps Research Institute | Protein arrays |
| JP5642916B2 (ja) * | 2003-04-17 | 2014-12-17 | ザ スクリプス リサーチ インスティテュート | 真核遺伝コードの拡張 |
| EP2410331B1 (en) * | 2003-06-18 | 2015-09-23 | The Scripps Research Institute | Aminoacyl-tRNA synthetase for aminoacylation tRNA with unnatural amino acids |
| WO2005007624A2 (en) * | 2003-07-07 | 2005-01-27 | The Scripps Research Institute | Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof |
| US20060160175A1 (en) * | 2003-07-07 | 2006-07-20 | The Scripps Research Institute | Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof |
| EP1649004A4 (en) * | 2003-07-07 | 2008-04-09 | Scripps Research Inst | COMPOSITIONS WITH PAIRS OF ORTHOGONAL LYSYL-TRNA AND AMINOACYL-TRNA-SYNTHETASE AND USES THEREOF |
| PT1687401E (pt) * | 2003-10-14 | 2013-02-26 | Scripps Research Inst | Incorporação de aminoácidos activos em oxidação-redução específica do local em proteínas |
| US7741071B2 (en) * | 2003-12-18 | 2010-06-22 | The Scripps Research Institute | Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells |
| JP2008500050A (ja) * | 2004-05-25 | 2008-01-10 | ザ スクリップス リサーチ インスティテュート | 結晶構造決定のための重原子含有非天然アミノ酸の部位特異的蛋白質組込み |
| AU2005286722B2 (en) * | 2004-09-21 | 2010-12-02 | The Scripps Research Institute | In vivo incorporation of alkynyl amino acids into proteins in eubacteria |
| US20090181858A1 (en) * | 2004-09-21 | 2009-07-16 | The Scripps Research Institute | Adding photoregulated amino acids to the genetic code |
| US20080171317A1 (en) * | 2004-09-22 | 2008-07-17 | The Scripps Research Institute | Site-Specific Labeling of Proteins for Nmr Studies |
| JP2008516637A (ja) * | 2004-10-20 | 2008-05-22 | ザ スクリップス リサーチ インスティテュート | 真正細菌へのｎ−アセチルガラクトサミンアミノ酸のインビボ部位特異的組込み |
| CN101048506B (zh) * | 2004-10-27 | 2013-06-26 | 斯克利普斯研究院 | 体内掺入非天然氨基酸的正交翻译组分 |
| FR2888097B1 (fr) * | 2005-07-06 | 2007-10-05 | Oreal | Dispositif de conditionnement et d'application comportant un organe d'essorage |
| BRPI0617191A2 (pt) * | 2005-10-12 | 2011-07-19 | Scripps Research Inst | modificação pós-traducional de polipeptìdeos expressos em fagos |
| KR20080106430A (ko) * | 2006-03-09 | 2008-12-05 | 더 스크립스 리서치 인스티튜트 | 진정 세균 숙주 세포 내에서의 직교형 번역 성분의 발현을 위한 시스템 |
| WO2007109035A2 (en) * | 2006-03-16 | 2007-09-27 | The Scripps Research Institute | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine |
| AU2007267950B2 (en) | 2006-05-23 | 2012-08-16 | The Scripps Research Institute | Genetically encoded fluorescent coumarin amino acids |
| US7421795B2 (en) * | 2006-08-04 | 2008-09-09 | Seagate Technology Llc | Sapphire alignment fixture |
| JP5385143B2 (ja) * | 2006-09-21 | 2014-01-08 | ザ スクリプス リサーチ インスティチュート | 真正細菌における選択的に硫酸化された蛋白質の遺伝的にプログラムされた発現 |
| WO2008073184A2 (en) * | 2006-10-18 | 2008-06-19 | The Scripps Research Institute | Genetic incorporation of unnatural amino acids into proteins in mammalian cells |
| TWI334126B (en) * | 2007-07-17 | 2010-12-01 | Au Optronics Corp | Voltage adjusting circuit, method, and display apparatus having the same |
| JP4978419B2 (ja) * | 2007-10-23 | 2012-07-18 | 富士ゼロックス株式会社 | 光送受信モジュール |
| US8673591B2 (en) * | 2007-10-25 | 2014-03-18 | The Scripps Research Institute | Genetic incorporation of 3-aminotyrosine into reductases |
| WO2009059056A2 (en) | 2007-11-02 | 2009-05-07 | The Scripps Research Institute | A genetically encoded boronate amino acid |
| JP5513398B2 (ja) * | 2007-11-02 | 2014-06-04 | ザ スクリプス リサーチ インスティチュート | 非天然アミノ酸を含有する蛋白質を使用する指向的進化 |
| WO2009064416A2 (en) | 2007-11-15 | 2009-05-22 | The Scripps Research Institute | Genetic incorporation of an alpha-hydroxy acid into proteins to generate ester backbone linkages at defined sites |
| US8218509B2 (en) * | 2008-01-15 | 2012-07-10 | Apple Inc. | Dynamic allocation of communication resources in a wireless system |
| EP2249865A4 (en) * | 2008-02-08 | 2012-04-04 | Scripps Research Inst | BREAKING IMMUNOLOGICAL TOLERANCE WITH A GENETICALLY ENCODED UNNATURAL AMINO ACID |
| WO2009151491A2 (en) | 2008-02-27 | 2009-12-17 | The Scripps Research Institute | In vivo incorporation of an unnatural amino acid comprising a 1,2-aminothiol group |
| US8609383B2 (en) * | 2008-12-10 | 2013-12-17 | The Scripps Research Institute | Production of carrier-peptide conjugates using chemically reactive unnatural amino acids |
| US20090197339A1 (en) * | 2008-12-10 | 2009-08-06 | The Scripps Research Institute | In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris |
| WO2010114615A2 (en) | 2009-04-03 | 2010-10-07 | The Scripps Research Institute | A facile system for encoding unnatural amino acids in mammalian cells |
-
2002
- 2002-04-19 WO PCT/US2002/012465 patent/WO2002085923A2/en not_active Ceased
- 2002-04-19 JP JP2002583590A patent/JP2004537984A/ja active Pending
- 2002-04-19 EP EP14167479.6A patent/EP2796546B1/en not_active Expired - Lifetime
- 2002-04-19 DK DK02725743.5T patent/DK1490483T3/en active
- 2002-04-19 DK DK10182672.5T patent/DK2322631T3/en active
- 2002-04-19 US US10/126,931 patent/US7083970B2/en not_active Expired - Lifetime
- 2002-04-19 MX MXPA03009563A patent/MXPA03009563A/es active IP Right Grant
- 2002-04-19 EP EP10182672.5A patent/EP2322631B1/en not_active Expired - Lifetime
- 2002-04-19 AU AU2002303431A patent/AU2002303431C1/en not_active Expired
- 2002-04-19 EP EP02731454.1A patent/EP1456360B1/en not_active Expired - Lifetime
- 2002-04-19 IL IL15841902A patent/IL158419A0/xx unknown
- 2002-04-19 IL IL15841802A patent/IL158418A0/xx active IP Right Grant
- 2002-04-19 WO PCT/US2002/012635 patent/WO2002086075A2/en not_active Ceased
- 2002-04-19 DK DK09006800.8T patent/DK2128246T3/da active
- 2002-04-19 CA CA2444098A patent/CA2444098C/en not_active Expired - Lifetime
- 2002-04-19 EP EP09006800.8A patent/EP2128246B1/en not_active Expired - Lifetime
- 2002-04-19 JP JP2002583449A patent/JP2005502322A/ja active Pending
- 2002-04-19 MX MXPA03009566A patent/MXPA03009566A/es active IP Right Grant
- 2002-04-19 CA CA2443757A patent/CA2443757C/en not_active Expired - Lifetime
- 2002-04-19 AU AU2002256292A patent/AU2002256292C1/en not_active Expired
- 2002-04-19 EP EP02725743.5A patent/EP1490483B1/en not_active Expired - Lifetime
- 2002-04-19 DK DK02731454.1T patent/DK1456360T3/en active
- 2002-04-19 US US10/126,927 patent/US7045337B2/en not_active Expired - Lifetime
- 2002-04-19 ES ES09006800.8T patent/ES2464532T3/es not_active Expired - Lifetime
-
2003
- 2003-10-15 IL IL158419A patent/IL158419A/en active IP Right Grant
-
2004
- 2004-12-01 US US11/002,387 patent/US7713721B2/en not_active Expired - Lifetime
- 2004-12-10 US US11/009,635 patent/US8183012B2/en not_active Expired - Fee Related
- 2004-12-17 US US11/017,550 patent/US20050250183A1/en not_active Abandoned
-
2005
- 2005-10-18 US US11/254,170 patent/US7354761B2/en not_active Expired - Lifetime
- 2005-10-18 US US11/254,161 patent/US7368275B2/en not_active Expired - Lifetime
-
2006
- 2006-10-18 US US11/583,551 patent/US7638300B2/en not_active Expired - Lifetime
-
2007
- 2007-05-04 US US11/800,455 patent/US7915025B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,188 patent/US8114648B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,108 patent/US8030074B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,156 patent/US8173392B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,154 patent/US8012739B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,157 patent/US20090068717A1/en not_active Abandoned
- 2007-10-26 US US11/978,221 patent/US8173364B2/en not_active Expired - Fee Related
- 2007-10-26 US US11/978,217 patent/US20110027867A1/en not_active Abandoned
- 2007-11-22 IL IL187588A patent/IL187588A/en active IP Right Grant
- 2007-11-29 IL IL187775A patent/IL187775A0/en active IP Right Grant
-
2008
- 2008-11-06 JP JP2008285996A patent/JP2009132704A/ja active Pending
- 2008-11-06 JP JP2008285997A patent/JP2009077731A/ja active Pending
-
2009
- 2009-01-26 IL IL196714A patent/IL196714A/en active IP Right Grant
- 2009-01-28 IL IL196762A patent/IL196762A/en active IP Right Grant
-
2010
- 2010-09-21 JP JP2010211248A patent/JP5766925B2/ja not_active Expired - Lifetime
-
2011
- 2011-06-15 US US13/161,335 patent/US20120101006A1/en not_active Abandoned
- 2011-08-02 US US13/196,829 patent/US20120202243A1/en not_active Abandoned
-
2012
- 2012-05-18 US US13/475,792 patent/US9163271B2/en not_active Expired - Fee Related
-
2013
- 2013-07-26 JP JP2013156012A patent/JP6239888B2/ja not_active Expired - Lifetime
-
2015
- 2015-04-29 HK HK15104166.3A patent/HK1203558A1/en unknown
-
2016
- 2016-02-08 JP JP2016021701A patent/JP6294368B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8173392B2 (en) | In vivo incorporation of unnatural amino acids | |
| AU2002256292A1 (en) | In vivo incorporation of unnatural amino acids | |
| AU2008200780B2 (en) | In vivo incorporation of unnatural amino acids | |
| HK1158259B (en) | Methods and compositions for the production of orthogonal trna-aminoacyl-trna synthetase pairs | |
| HK1069848B (en) | In vivo incorporation of unnatural amino acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |